Savolitinib plus osimertinib may be a chemotherapy-free treatment option for patients with EGFR-mutant, advanced NSCLC with MET overexpression/amplification whose disease has progressed on osimertinib ...
Beerse: Janssen-Cilag International NV, a Johnson & Johnson company, has received approval from the European Commission (EC) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback